Expert Review of Anti-infective Therapy最新文献_第7页

From Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Perspectives in Pediatric Patients with Chronic Hepatitis B. 从富马酸替诺福韦二吡呋酯（TDF）到替诺福韦阿拉非酰胺（TAF）：儿科患者的视角。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-12-01 Epub Date: 2024-10-09 DOI: 10.1080/14787210.2024.2412991

Minna Rodrigo, Christopher Hartley, Paul Wasuwanich, Trung Van, Wikrom Karnsakul

{"title":"From Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Perspectives in Pediatric Patients with Chronic Hepatitis B.","authors":"Minna Rodrigo, Christopher Hartley, Paul Wasuwanich, Trung Van, Wikrom Karnsakul","doi":"10.1080/14787210.2024.2412991","DOIUrl":"10.1080/14787210.2024.2412991","url":null,"abstract":"Introduction: Hepatitis B virus (HBV) affects hundreds of millions globally, with many cases stemming from perinatal transmission. Chronic hepatitis B (CHB) in children can progress to cirrhosis and hepatocellular carcinoma (HCC) in adulthood. Treatment options include interferons and nucleos(t)ide reverse transcriptase inhibitors (N[t]RTIs) such as tenofovir alafenamide (TAF).Areas covered: This review covers the epidemiology of pediatric CHB and current treatments, with a focus on tenofovir-based therapies, particularly tenofovir disoproxil fumarate (TDF) and TAF. TDF has been used for years, but its risks of bone mineral density loss and renal impairment have raised concerns. TAF, with lower systemic exposure, appears to mitigate these risks. Ongoing trials are evaluating TAF's safety in younger children. There are knowledge gaps in long-term safety and the potential for combination therapies.Expert opinion: TAF offers a safer alternative to TDF for children with CHB, showing high antiviral efficacy and fewer side effects. However, more data are needed on its use in younger children and long-term safety. The future of CHB treatment in pediatrics may include combination therapies and personalized approaches, potentially improving outcomes and minimizing risks over a lifetime of treatment. As research progresses, TAF is likely to become a cornerstone in pediatric CHB management.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1099-1106"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The efficacy and safety of hydroxychloroquine at different doses and courses for COVID-19 prevention: a systematic review and network meta-analysis. 不同剂量和疗程的羟氯喹预防 COVID-19 的有效性和安全性：系统综述和网络荟萃分析。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-12-01 Epub Date: 2024-10-09 DOI: 10.1080/14787210.2024.2413419

Hang Wang, Qiyuan Yang, Yinjun Mao, Haibo Ding, Pinfang Huang, Zhikun Zhan

{"title":"The efficacy and safety of hydroxychloroquine at different doses and courses for COVID-19 prevention: a systematic review and network meta-analysis.","authors":"Hang Wang, Qiyuan Yang, Yinjun Mao, Haibo Ding, Pinfang Huang, Zhikun Zhan","doi":"10.1080/14787210.2024.2413419","DOIUrl":"10.1080/14787210.2024.2413419","url":null,"abstract":"Background: The optimal strategy for using hydroxychloroquine to prevent coronavirus disease 2019 (COVID-19) in patients, either before or after exposure, remains unclear. We evaluated the safety and efficacy of different doses and treatment durations of hydroxychloroquine for COVID-19 prevention.Method: Databases including PubMed, Web of Science, Cochrane Library, EMBASE, Medline, and ClinicalTrials.gov were systematically searched for randomized controlled trials (RCTs) comparing different doses of hydroxychloroquine for COVID-19 prevention, from their inception to February 2024.Results: A total of 20 RCTs involving 12,372 patients were included. Meta-analysis results showed no significant difference between the hydroxychloroquine and control groups in reducing the incidence of syndrome coronavirus type 2 (SARS-CoV-2) positivity (OR = 0.83, 95% CI = 0.67, 1.03). However, the subgroup receiving a daily dose of 200-400 mg (OR = 0.62, 95% CI = 0.51, 0.75) and a treatment duration of 5-8 weeks (OR = 0.52, 95% CI = 0.31, 0.88) showed statistically significant reductions in SARS-CoV-2 positivity. According to the surface under the cumulative ranking curve (SUCRA), the most effective intervention was a 200-400 mg dose for 5-8 weeks. .Conclusions: A hydroxychloroquine dose of 200-400 mg for a duration of 5-8 weeks may moderately reduce the risk of COVID-19 with a relatively low risk of adverse events.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1209-1220"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ursodeoxycholic acid and COVID-19 outcomes: a cohort study and data synthesis of state-of-art evidence. 熊去氧胆酸与 COVID-19 结果：一项队列研究和最新证据数据综述。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-12-01 Epub Date: 2024-07-09 DOI: 10.1080/14787210.2024.2376153

Yang Yu, Guo-Fu Li, Jian Li, Lu-Yao Han, Zhi-Long Zhang, Tian-Shuo Liu, Shu-Xin Jiao, Yu-Wei Qiao, Na Zhang, De-Chuan Zhan, Shao-Qiu Tang, Guo Yu

{"title":"Ursodeoxycholic acid and COVID-19 outcomes: a cohort study and data synthesis of state-of-art evidence.","authors":"Yang Yu, Guo-Fu Li, Jian Li, Lu-Yao Han, Zhi-Long Zhang, Tian-Shuo Liu, Shu-Xin Jiao, Yu-Wei Qiao, Na Zhang, De-Chuan Zhan, Shao-Qiu Tang, Guo Yu","doi":"10.1080/14787210.2024.2376153","DOIUrl":"10.1080/14787210.2024.2376153","url":null,"abstract":"Background: The potential of ursodeoxycholic acid (UDCA) in inhibiting angiotensin-converting enzyme 2 was demonstrated. However, conflicting evidence emerged regarding the association between UDCA and COVID-19 outcomes, prompting the need for a comprehensive investigation.Research design and methods: Patients diagnosed with COVID-19 infection were retrospectively analyzed and divided into two groups: the UDCA-treated group and the control group. Kaplan-Meier recovery analysis and Cox proportional hazards models were used to evaluate the recovery time and hazard ratios. Additionally, study-level pooled analyses for multiple clinical outcomes were performed.Results: In the 115-patient cohort, UDCA treatment was significantly associated with a reduced recovery time. The subgroup analysis suggests that the 300 mg subgroup had a significant (adjusted hazard ratio: 1.63 [95% CI, 1.01 to 2.60]) benefit with a shorter duration of fever. The results of pooled analyses also show that UDCA treatment can significantly reduce the incidence of severe/critical diseases in COVID-19 (adjusted odds ratio: 0.68 [95% CI, 0.50 to 0.94]).Conclusions: UDCA treatment notably improves the recovery time following an Omicron strain infection without observed safety concerns. These promising results advocate for UDCA as a viable treatment for COVID-19, paving the way for further large-scale and prospective research to explore the full potential of UDCA.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1239-1250"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current understanding of infection of the ventricles and its complications. 目前对脑室感染及其并发症的认识。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-12-01 Epub Date: 2024-08-30 DOI: 10.1080/14787210.2024.2395018

Hazim Allos, Rodrigo Hasbun

{"title":"Current understanding of infection of the ventricles and its complications.","authors":"Hazim Allos, Rodrigo Hasbun","doi":"10.1080/14787210.2024.2395018","DOIUrl":"10.1080/14787210.2024.2395018","url":null,"abstract":"Introduction: Ventriculitis, characterized by inflammation of the ventricles in the brain, frequently occurs as a complication of neurosurgical interventions such as the insertion of cerebrospinal fluid (CSF) shunts or external ventricular drains. It can also present as a community-acquired pathology, broadening its clinical significance and complicating diagnosis and treatment. This condition presents significant challenges, primarily due to its association with various medical devices and the predisposing conditions of patients which enhance infection risks.Areas covered: The review comprehensively explores the etiology, risk factors, diagnostic methodologies, and treatment options for ventriculitis. A thorough literature search was conducted, focusing on recent studies, meta-analyses, and clinical reports that discuss the incidence rates, the effectiveness of different management strategies, and the impact of device-related and community-acquired infections. Particular attention is given to the role of CSF drains and shunts, biofilms, and the prophylactic measures employed in clinical settings to mitigate infection risks.Expert opinion: Despite advances in medical technology and infection control protocols, ventriculitis remains a severe complication in both neurosurgical and community settings. The review highlights the need for continued research into innovative diagnostic tools and more effective infection control strategies.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1023-1042"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142008538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MazEF toxin-antitoxin systems: their role in Mycobacterium tuberculosis stress response and drug resistance. MazEF 毒素-抗毒素系统：它们在结核分枝杆菌应激反应和抗药性中的作用。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-11-01 Epub Date: 2024-09-12 DOI: 10.1080/14787210.2024.2403021

Zoozeal Thakur, Renu Chaudhary, Promod K Mehta

引用次数: 0

Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex. 舒巴坦-杜鲁巴坦用于治疗鲍曼不动杆菌-醋酸钙复合菌。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-11-01 Epub Date: 2024-09-08 DOI: 10.1080/14787210.2024.2400703

Jordan R Covvey, Anthony J Guarascio

{"title":"Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex.","authors":"Jordan R Covvey, Anthony J Guarascio","doi":"10.1080/14787210.2024.2400703","DOIUrl":"10.1080/14787210.2024.2400703","url":null,"abstract":"Introduction: Infections with Acinetobacter baumannii-calcoaceticus complex (ABC) pose difficulty for clinicians given a limited arsenal of effective antimicrobials. Sulbactam/durlobactam provides a novel treatment option for patients experiencing hospital- or ventilator-acquired pneumonia with susceptible strains.Areas covered: This review provides a comprehensive discussion of sulbactam/durlobactam, including basic characteristics, in vitro activity, and clinical trial data supporting its use for the treatment of ABC. Manufacturer's data, published literature to date, and conference data are utilized in this review.Expert opinion: Sulbactam/durlobactam offers clinicians a new and effective treatment option for resistant ABC infection. Sulbactam, when combined with durlobactam, displays enhanced potency against ABC isolates, which has translated into positive clinical outcomes observed in clinical trials and post-marketing case studies. Although overall treatment indications and clinical experience are limited to date, sulbactam/durlobactam offers a familiar and favorable safety profile in comparison with alternative agents. Factors associated with use of combination antibiotic therapy, availability of commercial drug susceptibility testing, and cost-effectiveness are all currently key considerations for sulbactam/durlobactam use.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"925-934"},"PeriodicalIF":4.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical pharmacokinetics of antimicrobials in critical care: a narrative review. 重症监护中抗菌药物的临床药代动力学：叙述性综述。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-11-01 Epub Date: 2024-09-24 DOI: 10.1080/14787210.2024.2406466

Ritika Kondel Bhandari, Rachna Rohilla, Nusrat Shafiq, Avaneesh Kumar Pandey, Samir Malhotra

{"title":"Clinical pharmacokinetics of antimicrobials in critical care: a narrative review.","authors":"Ritika Kondel Bhandari, Rachna Rohilla, Nusrat Shafiq, Avaneesh Kumar Pandey, Samir Malhotra","doi":"10.1080/14787210.2024.2406466","DOIUrl":"10.1080/14787210.2024.2406466","url":null,"abstract":"Introduction: The management of critically ill septic patients presents considerable challenges due to multifaceted physiological alterations. Rapid changes such as fluid shifts, hyperdynamic states, and altered renal clearance often require special attention for better clinical outcomes. Vital organ dysfunction, with or without MODS, often necessitates supportive management like RRT, ventilatory support, and ECMO. These interventions can significantly affect the PK/PD of administered antimicrobials, complicating effective treatment.Area covered: Patient-specific parameters such as age, weight, and comorbid illnesses (e.g. cystic fibrosis, burns, and immunocompromised states) are critical determinants of antimicrobial pharmacokinetics. Understanding PK/PD determinants is crucial for developing optimized dosing regimens that enhance therapeutic efficacy and minimize toxicity in critically ill patients.Expert opinion: Incorporating pharmacometrics approaches in dose optimization can significantly improve patient outcomes. This review focuses on the nuances of PK/PD for optimized antimicrobial dosing in critically ill septic patients, emphasizing the importance of individualized treatment plans to address the complex and dynamic needs of this patient population. The adoption of these advanced pharmacokinetic and pharmacodynamic principles into clinical practice is essential for advancing patient care and optimizing therapeutic outcomes in critically ill patients.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"951-964"},"PeriodicalIF":4.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of outpatient fluoroquinolone prescribing with the National Medical Products Administration announcements of label changes in China. 中国门诊氟喹诺酮类药物处方与国家医药产品监督管理局标签变更公告的关联。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-11-01 Epub Date: 2024-06-20 DOI: 10.1080/14787210.2024.2368823

Houyu Zhao, Yexiang Sun, Xi Yao, Peng Shen, Hongbo Lin, Siyan Zhan

{"title":"Association of outpatient fluoroquinolone prescribing with the National Medical Products Administration announcements of label changes in China.","authors":"Houyu Zhao, Yexiang Sun, Xi Yao, Peng Shen, Hongbo Lin, Siyan Zhan","doi":"10.1080/14787210.2024.2368823","DOIUrl":"10.1080/14787210.2024.2368823","url":null,"abstract":"Background: In 2017 and 2021, the National Medical Products Administration (NMPA) announced to revise the drug label of fluoroquinolones. We aimed to evaluate the association of fluoroquinolone prescribing with the NMPA announcements of label changes.Research design and methods: Monthly prevalence of fluoroquinolone prescriptions for uncomplicated urinary tract infections (uUTI), acute exacerbation of chronic bronchitis (AECB), and acute sinusitis (AS) between 2016 and 2022 was calculated, and interrupted time series analysis was applied to assess the impacts of NMPA label changes on fluoroquinolone use.Results: Prevalence of fluoroquinolone prescriptions decreased by 2.39% (95% CI, -4.72% to -0.07%) for uUTI but increased by 3.02% (95% CI, 1.71% to 4.34%) for AS immediately after the 2017 label change. Moreover, after the 2021 label change, fluoroquinolone use decreased shortly in all the three indications. However, a significant increasing trend was observed in fluoroquinolone use for AECB episodes, and fluoroquinolons were used for 61.4% of treated uUTI, 31.6% of treated AECB, and 5.42% of treated AS at the end of 2022, respectively.Conclusions: The label changes issued by the NMPA had no substantial impacts on fluoroquinolone prescribing in the study region in China. Fluoroquinolone prescribing was still highly prevalent for uUTI and AECB and thus requiring further antimicrobial stewardship.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1007-1015"},"PeriodicalIF":4.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monotherapy versus combination for the treatment of Stenotrophomonas maltophilia: a multicenter cohort study. 单药与联合用药治疗嗜麦芽霉单胞菌病：一项多中心队列研究。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-11-01 Epub Date: 2024-05-13 DOI: 10.1080/14787210.2024.2353704

Thamer A Almangour, Hussain A Alali, Zakiyah Alkherb, Shuroug A Alowais, Khalid Bin Saleh, Sara Almuhisen, Abdullah Almohaizeie, Renad Alsahli, Shatha Alruwaite, Fai Alnashmi, Lolwa Fetyani, Noran Ibrahim Abouobaid, Alnajla Alghofaily, Khalifa M Binkhamis, Yazed Saleh Alsowaida

{"title":"Monotherapy versus combination for the treatment of Stenotrophomonas maltophilia: a multicenter cohort study.","authors":"Thamer A Almangour, Hussain A Alali, Zakiyah Alkherb, Shuroug A Alowais, Khalid Bin Saleh, Sara Almuhisen, Abdullah Almohaizeie, Renad Alsahli, Shatha Alruwaite, Fai Alnashmi, Lolwa Fetyani, Noran Ibrahim Abouobaid, Alnajla Alghofaily, Khalifa M Binkhamis, Yazed Saleh Alsowaida","doi":"10.1080/14787210.2024.2353704","DOIUrl":"10.1080/14787210.2024.2353704","url":null,"abstract":"Background: The aim of this study was to compare the safety and effectiveness of monotherapy versus combination therapy for the treatment of infections caused by S. maltophilia.Methods: This retrospective, multicenter, cohort study included patients treated with either monotherapy or combination therapy for infections caused by S. maltophilia. Primary outcomes included overall in-hospital mortality, 30-day mortality, and clinical cure. Safety outcomes were also evaluated. Multivariable logistic regression was used as a control for confounding variables.Results: A total of 407 patients were included, 330 patients received monotherapy and 77 patients received combination therapy. A total of 21% presented with concomitant bacteremia. After adjusting the differences between the two groups, there were no statistically significant differences between patients who received monotherapy versus combination therapy in clinical cure (55% vs 65%; OR, 0.72; 95% CI, 0.40-1.31) and overall in-hospital mortality (52% vs 49%; OR, 0.84; 95% CI, 0.45-1.57). However, patients who received monotherapy had a lower rate of 30-day mortality (28% vs 32%; OR, 0.45; 95% CI, 0.22-0.90) and acute kidney injury (9% vs 18%; OR, 0.35; 95% CI, 0.16-0.78).Conclusion: Clinical outcomes did not significantly differ in patients who received combination therapy versus monotherapy. More data are needed to validate these findings.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"997-1005"},"PeriodicalIF":4.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140910731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of recently-approved oral antiviral medications on the outcome of patients with mild-to-moderate COVID-19 and pre-existing chronic obstructive pulmonary diseases. 最近批准的口服抗病毒药物对轻度至中度 COVID-19 和原有慢性阻塞性肺病患者疗效的影响。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-11-01 Epub Date: 2024-05-08 DOI: 10.1080/14787210.2024.2351571

Bo-Wen Shiau, Wan-Hsuan Hsu, Ya-Wen Tsai, Jheng-Yan Wu, Ting-Hui Liu, Po-Yu Huang, Min-Hsiang Chuang, Chih-Cheng Lai, Lih-Wen Jang

{"title":"Effectiveness of recently-approved oral antiviral medications on the outcome of patients with mild-to-moderate COVID-19 and pre-existing chronic obstructive pulmonary diseases.","authors":"Bo-Wen Shiau, Wan-Hsuan Hsu, Ya-Wen Tsai, Jheng-Yan Wu, Ting-Hui Liu, Po-Yu Huang, Min-Hsiang Chuang, Chih-Cheng Lai, Lih-Wen Jang","doi":"10.1080/14787210.2024.2351571","DOIUrl":"10.1080/14787210.2024.2351571","url":null,"abstract":"Objectives: This study assessed the effectiveness of the oral antiviral agents nirmatrelvir - ritonavir (NMV-r) and molnupiravir (MOV) for treating mild-to-moderate coronavirus disease 2019 (COVID-19) in patients with COPD.Methods: This retrospective cohort study extracted data from the TriNetX platform and examined 94,984 COVID-19 patients with preexisting COPD from 1 January 2022, to 1 October 2023. Patients receiving NMV-r or MOV (study group) were compared with those not receiving oral antiviral agents (control group) after propensity score matching (PSM).Results: After PSM, 7,944 patients were classified into the study and control groups. The primary composite outcome of all-cause hospitalization, or death in 30 days was reported in 458 (5.7%) patients in the study group and 566 (7.1%) patients in the control cohort, yielding a hazard ratio [HR] of 0.79 (95% confidence interval [CI]: 0.70-0.89; Table 2). Compared with the control group, the study group had a significantly lower risk of all-cause hospitalization (HR, 0.87; 95% CI: 0.76-0.99) and death (HR: 0.21, 95% CI: 0.13-0.35).Conclusions: This study revealed that oral antivirals - NMV-r or MOV might improve clinical outcomes in patients with preexisting COPD and COVID-19. However, only a small proportion of preexisting COPD patients with COVID-19 received oral antiviral treatment.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"977-985"},"PeriodicalIF":4.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140850983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0